PlainPharmaWatch

CMS Open Payments · Program Year 2024

Stemline Therapeutics Inc.

Stemline Therapeutics Inc. reported $4,740,819.55 across General Payments, Research, and Ownership to 6,314 physicians and teaching hospitals across 6,720 transactions.

See the rankings → How this is sourced
$4.7M
All-tracks total
6,720
Transactions
6,314
Recipients
−$425.2K
General Payments vs PY2023

Stemline Therapeutics Inc. reported $4,740,819.55 across all CMS Open Payments tracks (General + Research + Ownership) to 6,314 physicians and teaching hospitals in Program Year 2024 - ranking #286 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,649,682.93, averaging $750.84 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer stemline-therapeutics-inc Stemline Therapeutics Inc.

$4.7M · #286/1,925 · 0.0% industry · PY2024

  • TOT $4.7M
  • RANK #286
  • SHARE 0.0%
  • TXN 6,720
  • RCP 6,314
  • CAT 6
  • GEN $1.6M
  • ΔGEN −$425.2K
  • TOP1 8.6%
  • PY 2024

Volume peers

Nearest volume peer: Novocure GmbH ($4.8M)

Inspire Medical Systems, Inc.$4.8MProgenics Pharmaceuticals, I…$4.8MTriSalus Life Sciences, Inc.$4.8MNovocure GmbH$4.8MStemline Therapeutics Inc. (…$4.7M
All-tracks payment totals near Stemline Therapeutics Inc. (CMS Open Payments PY2024)

Stemline Therapeutics Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Stemline Therapeutics Inc.'s CMS-reported General Payments decreased by $425.2K (−20.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: STEMLINE THERAPEUTICS INC.PY2023: STEMLINE THERAPEUTICS INC.PY2024: Stemline Therapeutics Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$2.1MPY2024$1.6M
PY2023
$2,074,879.36
PY2024
$1,649,682.93

What the Data Shows for Stemline Therapeutics Inc.

In Program Year 2024, Stemline Therapeutics Inc. reported $4,740,819.55 in payments to 6,314 physicians and teaching hospitals across 6,720 individual transactions, an average of $705.48 per transaction and $750.84 per recipient. That total places Stemline Therapeutics Inc. at rank #286 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

245 transactions worth $722.7K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 43.8% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 6 types of general payments, Stemline Therapeutics Inc.'s largest category was "Compensation for Services Other Than Consulting" at $722.7K - 43.8% of General Payments.

Stemline Therapeutics Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (43.8%), Consulting Fee (36.6%), and Food and Beverage (10.9%). The remaining 3 categories make up 8.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Stemline Therapeutics Inc. divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$722.7K2. Consulting Fee$604.5K3. Food and Beverage$179.8K4. Travel and Lodging$140.2K5. Honoraria$2.3K6. Education$91.03
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $722.7K 245
Consulting Fee $604.5K 153
Food and Beverage $179.8K 5,602
Travel and Lodging $140.2K 285
Honoraria $2.3K 12
Education $91.03 17

Recipient Concentration in General Payments

The five largest recipient relationships account for $509,059.68 (30.9%) of $1,649,682.93 in this company's General Payments records across 3,689 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Stemline Therapeutics Inc.

The five named recipients with the highest reported General Payments from this company

Samir Khleif$141.3KAnne P Odea$136.2KEnrique Garcia$117.7KFengting Yan$58.9KVijayakrishna Gadi$55.1K
  1. 1

    Samir Khleif

    $141,250.00 across 1 reported transactions

  2. 2

    Anne P Odea

    $136,175.95 across 86 reported transactions

  3. 3

    Enrique Garcia

    $117,700.00 across 4 reported transactions

  4. 4

    Fengting Yan

    $58,864.45 across 45 reported transactions

  5. 5

    Vijayakrishna Gadi

    $55,069.28 across 33 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Stemline Therapeutics Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Stemline Therapeutics Inc..

SK Life Science, Inc.

HHI 281

Agiliti Health, Inc.

HHI 278

True North Surgical Inc

HHI 281

Saluda Medical Americas, Inc.

HHI 278

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Stemline Therapeutics Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Stemline Therapeutics Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.